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Abstract
Introduction: Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis has been implicated in the pathology
of rheumatoid arthritis (RA), particularly as vulnerable personality types are exposed to chronic stress. Emotions are
powerful modulators of stress responses. However, little is known about whether patients with RA process
emotions differently to matched controls. In this study we: 1) assessed whether the trait emotional intelligence
(trait EI) scores of patients with RA differ from healthy controls at the facet level; 2) explored any subgroups in RA,
in terms of trait EI and common risk factors.
Methods: A total of 637 patients with RA were compared to 496 controls on the trait EI Questionnaire (TEIQue).
RA subgroups were explored in terms of trait EI, rheumatoid factor status (RF+/-), depression and time from onset
of symptoms until diagnosis (diagnostic delay).
Results: The RA group rated themselves lower on Adaptability, Stress-management, Emotion management, Self-
esteem, Sociability, Assertiveness, Impulsiveness and Well-being, and higher on Empathy and Relationships than
healthy controls. The RF- subtype reported more time with depression (25.2 vs. 11.3 months), a longer diagnostic
delay (3.0 vs. 1.7 years), and greater emotional expression (5.15 vs. 4.72), than the RF+ subtype. These differences
were significant at the P <0.05 level, but not following strict Bonferroni corrections and should therefore be treated
as indicative only. RF- patients with a longer diagnostic delay reported depression lasting three times longer (42.7
months), when compared to three other subtypes (11.0 to 12.7 months).
Conclusions: RA patients and controls differ in their emotion-related personality traits, as operationalized by trait
EI. These differences may make people with RA more susceptible to chronic stress and HPA-axis dysregulation. RA
may be a highly heterogeneous illness where at least two subtypes may be characterized by personality,
psychiatric and immunological differences. RF- status, as well as diagnostic delay and emotional expression, may
predict future risk of depression. Research on the causes of RA could benefit from a systems science approach.
Introduction
The causes of rheumatoid arthritis (RA) remain largely
unknown. Widespread agreement exists for only three
risk factors (female gender, family history of RA and
smoking tobacco [1]). These three cannot sufficiently
describe an individual’s risk of RA, suggesting that other
risk factors remain to be discovered [2]. One candidate
risk factor for the development of RA is psychological
stress [3]. For example, stressful life-events have pre-
ceded the onset of RA in as many as 86% of cases [4],
and higher stress at the onset of disease predicts worse
disease prognosis [5-7]. It has been suggested that peo-
ple with RA may be hypersensitive to certain stressors
and/or generate a bigger stress response [8].
Certain personality traits can amplify the stress response.
For example, people with the type A personality have
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increased levels of cortisol, epinephrine, C-reactive protein
(CRP), fibrinogen, HbA1C, high-density lipoprotein/total
cholesterol (HDL/TC), systolic blood pressure and body
mass index (BMI) [9]. People who report more hostility
also show increased levels of epinephrine, norepinephrine,
glucose, HDL/TC, systolic blood pressure and waist-to-hip
ratios [10]. Low novelty seeking and high harm avoidance
have both been linked to increased cortisol secretion in
response to the dexamethasone test [11]. Neuroticism and
introversion have been associated with a blunted hypotha-
lamic-pituitary-adrenal (HPA) axis response [12]. This all
suggests that personality traits may be linked to immune
dysregulation, which may be important for autoimmune
diseases, such as RA. While we are not aware of studies
linking stress biomarkers to the personality of patients
with RA, patients with RA have nonetheless been found to
be more perfectionistic and neurotic [13] than matched
controls. Theory would predict that patients with RA may
be more sensitive to negative stimuli and hence more
likely to trigger a stress response at lower thresholds [14].
Emotions are powerful modulators of stress-responses, but
modern personality inventories often neglect aspects of
personality that describe how one feels and processes
emotions. There could be value in explicitly exploring the
emotion-related personality traits of patients with RA. To
our knowledge, no such study has yet been done. Under-
standing these mechanisms may enable us to better pre-
dict the course of RA, and potentially develop specific
cognitive behavioural therapies [15-18].
We hypothesized that patients with RA may process
emotions differently to controls and decided to investi-
gate this using the personality trait emotional intelligence
(trait EI). Trait EI is defined as a constellation of emo-
tional self-perceptions concerning one’s abilities to recog-
nize, process and utilize emotion-laden information [19],
details of which are seen in the tables. An alternative
label for trait EI is “trait emotional self-efficacy”. Trait EI
should not be confused with seemingly related constructs
that try to objectively gauge how “Emotionally Intelli-
gent” one is, using IQ-like tests. Such tests have proved
less useful, since it can be difficult to agree on the correct
response to emotional questions. However, measuring EI
as a trait is more straightforward, as assessment is facili-
tated by self-report questionnaires, where there are no
right or wrong answers.
We have recently reported the broader results of a
related study where we compared overall trait EI scores of
healthy controls to various people with inflammatory con-
ditions [20]. Results showed that patients with RA have
only slightly lower scores in overall trait EI (4.90 ± 0.71)
when compared to controls (4.97 ± 0.61), a difference that
was non-significant in that sample. Significant differences
were also found in two of the four trait EI factors, with RA
patients rating themselves lower on Well-being and
Sociability than controls. The two-fold aim of the present
paper is to look more closely at the RA versus healthy
group comparison in terms of the 15 specific facets of trait
EI, as well as to explore any potential subtypes of RA.
Subtypes of RA
We explored the possibility of identifying potential sub-
types of RA, defined in terms of their trait EI scores.
Patients with RA have shown significant inter-individual
variation in genotype, gene expression, cytokine patterns,
rheumatoid factor (RF) levels, histopathology, microanat-
omy [21], clinical manifestations and response to treat-
ment [22]. For example, RF is present in only 70 to 80% of
patients with RA, and people can be RF+ without develop-
ing RA [23]. This literature suggests that RA may be
caused by multiple pathways, each of which is expressed
in a slightly different manner in each individual [24].
This perspective dictates that all studies on risk factors
should look not only for differences between cases and
non-cases, but also explore any potential differences in
risk factors between subgroups of cases. Researchers in
the 1960s to 1980s applied this perspective to the analy-
sis of the rheumatoid personality, which they suggested
is composed of two subtypes linked to RF status [25,26].
However, this idea has not been thoroughly investigated
in recent literature, so we decided to follow it up by
exploring any possible personality differences in trait EI
between the RF+ and RF- subgroups.
Most of the recent studies of personality in RA have
assumed that there are no pathological subtypes of RA,
and that there is only a single disease entity. As a result,
their samples would have comprised various combina-
tions of RF+ to RF- patient ratios. This may be responsi-
ble for some of the previous discrepancies in results,
particularly with regards to anger expression, impulsivity
and defiance [27]. We hypothesized that contradictory
findings could be resolved at the subgroup level and that
when comparing RF+ and RF- subgroups, we may find
differences in the trait EI facets of emotion expression,
impulsiveness and assertiveness.
RA and depression
The prevalence of depression in patients with RA is 13 to
42%, which is many times higher than in the general
population [28]. Two parallel mechanisms have been sug-
gested to explain this. First, disability from RA prevents
patients from functioning the way they used to, thus gen-
erating feelings of loss and depression [29]. Second, the
proinflammatory cytokine milieu that accompanies acute
flares in RA may have a direct neural effect in promoting
sickness behaviour and corresponding depressive symp-
toms. While studies of depression in RA have been
inconclusive about the role of such a pathway [30,31],
studies in stand-alone depression have found a significant
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inflammatory component [32], allowing anti-inflamma-
tories to be used as effective adjuncts in the treatment of
resistant depression [33,34]. It has been postulated that
good treatment of depression in RA may also lead to
synergistic improvements in the inflammatory compo-
nent of RA [35]. Stress-management training has
enhanced their cognitive-behavioural variables of self-
efficacy, helplessness and coping style, which in turn
have led to reduced pain and depression in patients with
RA [36,37]. Given the proximity of emotional processing
to the themes of stress-management, inflammation and
depression [38], we complemented our study with a brief
exploration of possible personality differences in trait EI
with respect to depression.
Materials and methods
A cross-sectional study was conducted to compare: a) the
trait EI profiles of RA patients against controls at the level
of the 15 trait EI facets, and b) the full trait EI profiles
between the RF+ and RF- subgroups. The research was
conducted in accordance with the Declaration of Helsinki,
and ethical approval was granted by the UCL Research
Ethics Committee. Patient societies were approached in
countries of comparable lifestyle (UK, Ireland, USA,
Canada, Australia, New Zealand). Societies in the UK and
Canada chose to participate, and emailed approximately
3,000 invitations to their members to complete our online
questionnaire. Informed consent was obtained from all
participants on our website. A total of 744 questionnaires
were received, of which 637 were fully completed. A total
of 496 healthy control subjects were randomly drawn
from the normative database of the trait EI instrument
used in the study (see Table 1 for a description of the sam-
ples). We used the Trait Emotional Intelligence Question-
naire (TEIQue) version 1.5 (Manufacturer: K. V. Petrides,
London Psychometric Laboratory, London, UK) [39], the
psychometric validity of which has been confirmed in
many independent studies [40]. Participants respond on a
7-point Likert scale, ranging from ‘completely disagree’ to
‘completely agree’. A total of 153 items are psychometri-
cally combined to derive 15 facet scores, which give rise to
four broad factors (Emotionality, Sociability, Self-control
and Well-being) and global trait EI.
For subgroup analysis, we also asked participants to
report brief details of known risk factors: rheumatoid fac-
tor status, current smoking status, alcohol intake, age at
onset of symptoms and age at diagnosis. Diagnostic delay
was calculated by subtracting age at onset of symptoms
from age at diagnosis. For ANOVA analysis, diagnostic
delay was divided into two categorical variables: patients
who took longer than 12 months to be diagnosed from the
onset of symptoms (delayed diagnosis), and patients who
took less than 12 months to be diagnosed from the onset
of symptoms (quick diagnosis). As a rapid estimate of the
extent of co-morbid depression, participants were also
asked to estimate the total number of months they had
been treated for depression throughout their lifetime.
Statistical analysis was conducted with SPSS Statistics
18.0 (Manufacturer: IBM, Armonk, New York, USA). A
series of t-tests were used to compare the continuous vari-
ables (trait EI profiles; age of onset; age of diagnosis; diag-
nostic delay; depression; alcohol consumption) across
categorical groups (patients vs. healthy controls; RF+
patients vs. RF- patients). The Bonferroni adjustment was
used to control for Type I error. A series of bivariate Pear-
son’s correlations were used to test for associations
between continuous variables. Two-way ANOVAs were
used to test for interactive effects between two categorical
groups (patients vs. healthy controls; males vs. females; RF
+ patients vs. RF- patients; quick diagnosis vs. delayed
diagnosis), on continuous dependent variables that
reached significance in previous one-way testing (namely
the four trait EI factors and the total number of months
spent on treatment for depression).
Results
Trait emotional intelligence in rheumatoid
arthritis vs. controls
Significant differences were found in 8 of the 15 underly-
ing personality facets, with the RA group rating them-
selves higher on relationships and empathy, and lower on
stress management, emotion management, adaptability,
Table 1 Table of demographics for the rheumatoid







49.3 (11.2) 41.5 (10.0)
Gender
male 44 (9.4%) 234 (46.8%)
female 424 (90.6%) 266 (53.2%)
Education
basic 107 (23.3%) 62 (12.9%)
technical 121 (26.3%) 85 (17.7%)
university 232 (50.4%) 334 (69.4%)
Annual Income
<£ 25,000 204 (51.8%) 166 (39.2%)
25,000 to 50,000 144 (36.5%) 153 (36.1%)
>50,000 46 (11.7%) 105 (24.8%)
Ethnic origin
white (U.K.) 301 (64.6%) 310 (66.2%)
white (other) 151 (32.4%) 81 (17.3%)
other 14 (3.0%) 77 (16.5%)
Marital status
single 159 (34.0%) 86 (18.8%)
married 305 (65.2%) 269 (58.7%)
living together 42 (9.0%) 53 (11.6%)
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assertiveness, impulsiveness and self-esteem (P <0.0025
following Bonferroni adjustment, Table 2). There was no
relationship between trait EI scores and the number of
years the patient had been ill, neither in the RA group as
a whole, nor in just those RA patients whose symptoms
started within the last five years.
Gender interactions
We tested for interactive effects between gender (male
vs. female) and group (patients vs. healthy controls) on
four trait EI factors (Figure 1).
Well-being: Significant main effects were found for
gender (F(1,960) = 8.20), P <0.01), group (F(1,960) =
21.5), P <0.01), as well as their interaction (F(1,960) =
8.53; P <0.01). While healthy males and females had
comparable scores in Well-being, RA males had signifi-
cantly lower Well-being scores than RA females.
Self-Control: Significant main effects were found for
gender (F(1,960) = 6.67, P <0.01), and the interaction (F
(1,960) = 5.11, P <0.05), but not for group (F(1,960) =
0.003, P = 0.96). On Self-control, RA males scored lower
than healthy males, while RA females scored higher than
healthy females. There were no main or interactive effects
with gender on the other two trait EI factors, Emotionality
and Sociability.
Subtypes within the RA group
We asked 286 patients with RA whether they knew their
rheumatoid factor (RF) status, of whom 222 patients
answered positively. A total of 157 patients (70.7%) had
been tested positive for rheumatoid factor (RF+), and 65
(29.3%) had been tested negative for rheumatoid factor
(RF-). A total of 292 patients answered concerning
whether they had received treatment for depression, of
whom 139 (47.6%) had received treatment at some
point in their lives, and 153 (52.4%) had never received
treatment for depression.
We explored whether the RF+ and RF- subgroups show
any differences in terms of their trait EI profiles or simple
disease characteristics (Table 3). Of the 20 trait EI scores,
the two groups scored very similarly on 13 scores with a
non-significant score difference of less than 0.15 points on
the Likert scale. On seven scores, small differences (0.15
to 0.3 points) were seen between the RF+ and RF- groups,
but these were non-significant (effect size Cohen’s d =
0.13 to 0.23). By content, these borderline differences sug-
gested that RF- patients may score slightly lower on stress
management, optimism, happiness, well-being, impulsivity
and slightly higher on assertiveness, when compared to
RF+ patients. On the emotion expression score, the differ-
ence was more pronounced (0.43 points, d = 0.33), with
Table 2 Trait Emotional Intelligence profile comparison between rheumatoid arthritis and healthy control groups
(means; t-tests)
Factor/Facet Rheumatoid arthritis (n = 637)
Mean (SD)
Healthy controls (n = 496)
Mean (SD)
t - value Effect size (Cohen’s d)
Well-being 5.10 (1.06) 5.27 (0.82) 3.03*** 0.18
Self esteem 4.76 (1.04) 4.97 (0.83) 3.79*** 0.22
Happiness 5.35 (1.31) 5.55 (1.01) 2.83** 0.17
Optimism 5.18 (1.18) 5.29 (0.98) 1.60 0.10
Self-control 4.65 (0.86) 4.66 (0.80) 0.14 0.01
Emotion regulation 4.53 (0.97) 4.56 (0.86) 0.60 0.03
Stress management 4.47 (1.11) 4.69 (0.99) 3.51*** 0.21
Low impulsiveness 4.97 (0.97) 4.73 (0.97) 4.05*** 0.25
Emotionality 5.21 (0.81) 5.08 (0.74) 2.66** 0.17
Emotion perception 4.92 (0.95) 4.89 (0.83) 0.50 0.03
Emotion expression 4.83 (1.36) 4.82 (1.21) 0.10 0.01
Relationships 5.71 (0.82) 5.46 (0.80) 5.26*** 0.31
Empathy 5.36 (0.83) 5.15 (0.79) 4.21*** 0.26
Sociability 4.70 (0.82) 4.95 (0.75) 5.39*** 0.32
Social awareness 4.90 (0.99) 5.04 (0.88) 2.37* 0.15
Emotion management 4.59 (0.82) 4.84 (0.85) 4.99*** 0.30
Assertiveness 4.60 (1.06) 4.98 (0.87) 6.46*** 0.39
Adaptability 4.55 (1.02) 4.74 (0.84) 3.26*** 0.20
Self-motivation 5.01 (0.91) 4.89 (0.82) 2.38* 0.14
Global trait
Emotional intelligence 4.92 (0.72) 4.97 (0.61) 1.45 0.08
*P (value) <0.05; **P (value) <0.01; ***P (value) <0.0025 following Bonferroni adjustment to control for experiment-wise Type I error.
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Figure 1 Interactive effects between gender and group (rheumatoid arthritis vs control) on two emotional intelligence factors.
Table 3 Comparison of rheumatoid factor + (RF+) and rheumatoid factor- (RF-) subgroups in terms of trait emotional
intelligence scores and other characteristics
RF+ (n = 157)
mean (SD)
RF- (n = 65)
mean (SD)
t - value Effect size
(Cohen’s d)
Personality facet Emotion expression 4.72 (1.29) 5.15 (1.34) 2.21* 0.33
Personality facet Optimism 5.23 (1.19) 4.94 (1.31) 1.60 0.23
Personality facet Happiness 5.34 (1.28) 5.04 (1.45) 1.53 0.22
Personality factor Well-being 5.11 (1.05) 4.88 (1.17) 1.44 0.21
Personality factor Emotionality 5.15 (0.73) 5.30 (0.82) 1.36 0.19
Personality facet Assertiveness 4.49 (0.98) 4.69 (1.05) 1.35 0.20
Personality facet Low impulsiveness 4.81 (1.01) 5.00 (0.92) 1.33 0.20
Personality facet Stress management 4.49 (1.00) 4.35 (1.14) 0.90 0.13
Personality facet Empathy 5.31 (0.74) 5.41 (0.87) 0.86 0.12
Personality facet Social awareness 4.90 (1.01) 4.79 (1.08) 0.70 0.11
Personality facet Self-esteem 4.76 (0.99) 4.66 (1.03) 0.69 0.10
Personality facet Emotion regulation 4.47 (0.88) 4.38 (0.98) 0.69 0.10
Personality facet Emotion perception 4.90 (0.89) 4.97 (1.01) 0.46 0.07
Personality factor Sociability 4.66 (0.85) 4.70 (0.87) 0.35 0.05
Personality facet Emotion management 4.58 (0.87) 4.62 (0.88) 0.31 0.05
Personality facet Relationships 5.67 (0.78) 5.68 (0.81) 0.11 0.01
Personality facet Self-motivation 4.93 (0.94) 4.94 (0.90) 0.10 0.01
Personality factor Self-control 4.59 (0.81) 4.58 (0.86) 0.10 0.01
Personality facet Adaptability 4.48 (0.98) 4.48 (1.10) 0.03 0.00
Global trait Emotional intelligence 4.87 (0.68) 4.87 (0.75) 0.02 0.00
Diagnostic delay (years from onset to diagnosis) 1.71 (3.33) 3.00 (5.23) 2.18* 0.30
Depression (months on treatment) 11.3 (33.0) 25.2 (72.7) 2.06* 0.26
Social class (8 = professional) 5.85 (2.11) 6.28 (1.73) 1.56 0.22
Age 49.1 (10.8) 46.8 (11.1) 1.43 0.21
Age of onset of symptoms 39.1 (12.7) 36.7 (14.6) 1.22 0.18
Annual Income (11 = ≥ £ 50 000) 5.30 (3.00) 5.64 (3.25) 0.70 0.11
Current smoker (1 = yes; 2 = no) 1.87 (0.34) 1.85 (0.36) 0.39 0.06
Exercise (hours/week) 1.75 (2.70) 1.88 (2.89) 0.32 0.05
Gender (2 = female) 1.93 (0.26) 1.94 (0.24) 0.23 0.04
Education (3 = university) 2.34 (0.77) 2.36 (0.78) 0.17 0.03
Alcohol (units/week) 7.52 (10.9) 7.33 (11.7) 0.09 0.02
*P (value) <0.05.
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RF- patients scoring higher on emotion expression than
RF+ patients. This was statistically significant at conven-
tional levels (P <0.05), but not after an experiment-wise
Bonferroni correction was applied (P >0.0025).
Comparison of other disease characteristics showed that
the RF+ and RF- groups were virtually identical in terms
of their demographics (education, income) and lifestyle
factors (alcohol, smoking, exercise). The RF- group was
2.3 years younger and developed symptoms 2.4 years later
than the RF+ group, and had a slight leaning toward
higher socioeconomic status. However, these differences
were not statistically significant. The RF- groups had spent
twice as much time being treated for depression (d =
0.26), and waiting nearly twice as long for their diagnosis
from disease onset (d = 0.30). This was statistically signifi-
cant at conventional levels (P <0.05), but not after an
experiment-wise Bonferroni correction was applied
(P >0.0025).
Two additional correlations were found to be statisti-
cally significant, even after a Bonferroni adjustment
(P <0.0025). Thus, “wait-time from symptom onset until
diagnosis” was positively correlated with the number of
months spent on treatment for depression (r = 0.285),
and negatively correlated with the age of onset of symp-
toms (r = 0.186).
Subsequently, a two-way ANOVA was conducted with
RF status and diagnostic delay as the independent vari-
ables, and the number of months spent on treatment for
depression as the dependent variable (Figure 2). Significant
main effects were found for both RF status (F(1,239) =
4.54, P <0.05) and diagnostic delay (F(1,239) = 5.72, P <
0.05), meaning that the RF- subgroup reported longer
treatment for depression than the RF+ subgroup. Those
whose diagnosis took longer than 12 months reported
more treatment for depression than those whose diagnosis
took less than 12 months. We also observed an interactive
effect (F(1,239) = 4.87, P <0.05), meaning that within the
RF+ subgroup, having a long diagnostic delay did not
increase the number of months spent on treatment for
depression. For the RF- subgroup, however, having a
longer diagnostic delay increased the number of months
spent on treatment for depression from 12 to 43 months.
Discussion
We found significant differences in 8 of the 15 trait Emo-
tional Intelligence facets, when comparing RA patients to
healthy controls. RA patients scored lower on assertive-
ness, self-esteem and impulsiveness. This agrees with ear-
lier descriptions of RA patients as shy, self-sacrificing and
compliant, suggesting that they place greater priority on
the needs of others as opposed to their own needs [41,42].
Such emotion-related personality traits are not fully repre-
sented in common personality inventories, such as the Big
Five of Openness, Conscientiousness, Extraversion, Agree-
ableness and Neuroticism. As a result of not looking for
this cluster of affective traits, some studies have concluded
that no personality differences exist between RA and
healthy control groups [43]. Our findings, however, lend
support to the conclusions of other studies that have spe-
cifically investigated such personality traits.
RA patients reported greater empathy and better rela-
tionships, but lower emotion management and stress
management than healthy controls. These facets have
not been previously investigated psychometrically in
rheumatoid populations, but similar themes have been
described, including lack of ‘emotional maturity’, and
‘struggling to contain hostile thoughts’ [44]. Since low
emotional control has been associated with greater levels
of pain [45] and worse rehabilitation outcomes [46], this
line of enquiry may have the potential to yield clinical
benefits in the future.
We also found RA patients to be less adaptable than
healthy controls. This trait too has received little atten-
tion in the RA personality literature, but corresponds
broadly with psychological rigidity [47]. Altogether,
these five emotion-related traits have not always been
included in personality inventories, which could explain
why these differences have not been previously detected.
We encourage their inclusion in future studies investi-
gating the personality of rheumatoid patients.
An interesting question is whether these emotion-
related personality differences arose as a consequence of
having to adapt to life with a debilitating condition or
whether they had been present before the onset of disease.
Unfortunately, we are not aware of any longitudinal study
of personality in rheumatoid arthritis that could help shed
light on this issue. Personality is generally stable over time,
particularly in the 40 to 60 age group of our participants
[48] although it can change under some situations, such as
major life events [49,50] or pregnancy [51]. Therefore, the
Figure 2 Mean number of months treated for depression,
across rheumatoid factor status and diagnostic delay.
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possibility remains that some of these personality differ-
ences may have arisen as a consequence of RA. Nonethe-
less, we feel that our data offer little support for this
perspective. For example, if personality changed in
response to the illness, we would expect some personality
scores to correlate with time spent being ill, particularly
during the first few years after onset. However, we found
no such correlation either in the RA group as a whole, or
in those RA patients whose onset started within the past
five years. Although by no means definitive, this suggests
that the personality differences we report may have been
present before the onset of the disease. Future cohort stu-
dies would be best placed to answer this question.
Seven out of eight significant personality differences are
consistent with the hypothesis that RA patients are less
good at controlling the build-up of chronic stress, com-
pared to healthy controls (relationships was the one facet
where the RA group scored higher). Looking at those
facets with the biggest effect sizes, the RA group scored
lower on assertiveness (d = 0.39) and emotion manage-
ment (d = 0.30). It is plausible that less assertive people
may develop more internal stress, the ineffective discharge
of which via maladaptive emotion management strategies
may cause such stress to persist or intensify. Chronic
stress may lead to over-activation and dysregulation of the
HPA axis, as well as dysregulation of the autonomic ner-
vous system [4]. This, in turn, can lead to inflammatory
dysregulation, which may precipitate and perpetuate rheu-
matoid arthritis in certain individuals [52-54].
Gender differences
We found that RA males have much lower scores in well-
being and self-control than control males. A similar signifi-
cant difference was found between RA females and control
females in well-being, but this difference was significantly
smaller in magnitude (Figure 1). To our knowledge, this is
the first study to describe personality differences in RA
with respect to gender. If these differences arose as a
response to illness, it suggests that men are particularly vul-
nerable to loss of well-being and self-control. Men may
benefit more from targeted cognitive behavioural therapy
to increase their self-confidence and positive affect, as well
as skills of emotional control, stress management and gen-
eral self-reflection [55]. If these personality differences were
present before disease onset, this suggests that men and
women develop RA along slightly different pathways,
wherein the role of personality manifests itself in a gender-
specific manner. Future studies investigating the determi-
nants of RA should explicitly look for gender-personality
interactions.
Significance of RA subtype associations
Many RF+ versus RF- differences reached levels of con-
ventional statistical significance, but these were lost after
the application of stringent Bonferroni corrections to con-
trol for experiment-wise error. One could take the strict
view and dismiss these findings as “not significant”. How-
ever, we decided to give these borderline associations the
benefit of the doubt, and comment on them in our discus-
sion. This is partly because explorative studies should
report results that were close to reaching significance, with
the intention to encourage further confirmatory studies.
Second, our sample size in these comparisons was very
small (n = 65 and 165 for RF- and RF+ groups), but the
mean differences were relatively large, suggesting that lar-
ger studies may well confirm these associations as statisti-
cally significant. Moreover, some of the associations we
uncovered could have been hypothesized by prior theory,
after which P <0.05 would have denoted statistical signifi-
cance. For example, literature suggests that RF- people
have a greater prevalence of psychological maladjustment
than RF+ people, making it plausible for RF- people to
spend more time with depression. In any case, while we
have elaborated fully on associations where 0.0025 <P
<0.05, we stress that our data are only indicative, and
require replication on larger studies.
RA subtypes by depression
The lifetime prevalence of depression in our RA group
was 47.6% (that is, 47.6% of patients had received some
treatment for depression during their lifetime). We are
not aware of previous literature describing the lifetime
prevalence of depression in RA. However, the lifetime
prevalence of depression is usually twice the current
prevalence at any given moment [56]. Using this heuris-
tic, we would expect the lifetime prevalence of depres-
sion in an RA population to be between 30 to 60%. Our
finding of 47.6% falls within this range, suggesting that
our sample was representative of the general RA popula-
tion, in terms of tendency towards depression.
RF- patients reported more time spent with depression
than RF+ patients. We are not aware of a similar finding
in previous literature [57]. RF- status has, however, been
linked to the covariates of depression, such as psychia-
tric disorders, psychoticism, anxiety and neuroticism
[26,58,59]. Furthermore, RF- status has been associated
with lower self-acceptance, greater psychological rigidity,
obsessive-compulsiveness, somatization complaints,
emotional detachment, reduced emotional functionality,
social alienation and paranoid ideation [25,60,61]. Our
novel finding that RF- patients tend to spend more time
being treated for depression is, therefore, consistent
with the existing literature profile of higher psychopathy
in RF- patients. This suggests that RF, a readily available
biomarker, may be a clinically useful risk factor for pre-
dicting subsequent depression in patients with RA. This
informs the on-going debate about the utility of RF test-
ing in clinical practice [62].
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We describe a further subgroup interaction that renders
some individuals particularly vulnerable to depression: RF-
patients for whom it took longer than 12 months to be
diagnosed since the onset of their symptoms, spent a sig-
nificantly longer period on treatment for depression
(mean = 43.2 months), compared to the three other sub-
groups (RF+, long diagnosis = 12.7 months; RF+, short
diagnosis = 11.0 months; RF-, short diagnosis = 11.7
months). This novel finding suggests that the “RF-, delayed
diagnosis” subtype may be especially vulnerable to devel-
oping recurrent depression, or simply resistant to current
methods of treating depression. Again, this subtype is
clinically easy to describe, so future studies could explore
whether they would benefit from earlier treatment for
depression, or a different treatment approach, in order to
prevent its recurrence.
RA subtypes by emotional expression and
diagnostic delay
RF- patients in our study reported greater levels of emo-
tional expression than RF+ patients. This matches pre-
vious descriptions of RF- patients displaying hostility and
aggression more readily than RF+ patients [63]. Emotional
expression is also related to emotional disclosure, which
has been associated with lower disease activity and better
health outcomes in RA [64,65]. In healthy volunteers,
emotional disclosure has been linked to short-term reduc-
tions in T-helper cells, T-killer cells, total lymphocyte
counts [66], greater brain congruence between left and
right hemispheres, reduced autonomic stress as measured
by skin conductance, as well as fewer somatic complaints
[67]. This body of work led us to the hypothesis that the
release of psychological stress via emotional expression
may protect the immune system (RF- patients). Conver-
sely, RF+ patients who tend to suppress or ‘bottle up’ psy-
chological stress may be causing some form of neuro-
immunological damage. This damage would add to other
pathological processes that eventually manifest as rheuma-
toid factor antibodies in the common, more severe subtype
of RA that is easier to diagnose.
If emotional expression gives immunological benefits to
the RF- subtype, then how can we explain its association
to psychological harm? This could be explained if
patients associate frequent emotional expression to
notions of failure or unattractiveness. Using psychody-
namic theory, we can speculate that people with RA may
begin with a common belief that others are more impor-
tant than themselves [68]. This creates a desire to sup-
press any self-centred thoughts and feelings [41]. Because
such feelings naturally rise in everyday life, we can sepa-
rate the two RA subtypes depending on how they
respond to such situations.
The RF+ subtype could be more successful in meeting
the demands of their super-ego, by suppressing their
emotions effectively. This reconciliation between the
desired self and the actual self can lead to psychological
well-being and stability. However, there can be a physical
flipside to the coin, whereby the suppression of ego-centric
thoughts may have negative consequences on immune
dysregulation (either directly or indirectly through media-
tors like the uptake of smoking). These processes ulti-
mately culminate with the production of rheumatoid
factor, more severe rheumatoid arthritis and a quicker
diagnosis. Further to the associations described above, RF
+ has also been associated with smoking [69], lower socio-
economic status [70], the DRB1*0401 gene [71], melatonin
receptor type 1 [72], reduced autonomic cardiovascular
reflexes [73], soluble granzymes [74], and reduced soluble
receptors for advanced glycation end products [75], all of
which leads to increased inflammation, more pentosidine
in the synovium [76] and a poorer response to anti-TNFa
therapy [77]. It remains to be seen precisely how our find-
ings may relate to these features of the RF+ subtype.
In contrast, the RF- subtype could be less successful at
controlling their self-centred emotional expressions. This
would create a conflict between the desired self and the
actual self, and generate feelings of guilt and remorse that
contribute to depression. On the flipside, perhaps it is this
subtype’s ability to discharge selfish wants and the ensuing
guilt, which gives their immune system protection against
HPA axis dysregulation and subsequent development of
rheumatoid factor [59]. The RF- subtype develops RA
along different pathways that are more associated with the
DRB1*0301 [78], DRB1*08, DRB1*11, SLC11A1 [79] and
HLA-B27 [80] genes, the use of the oral contraceptive pill
[81], and increased IL-1ss and IL-12p40 cytokines leading
to a monocyte-based inflammatory cascade [82]. The RF-
subtype is not associated to socioeconomic status. It is
important to remember that this discussion is speculative.
We provide it only to spur other researchers to consider
the wider associations that may be underlying each of the
various factors, so that the scientific community may start
to move toward a complex but integrated map of the
aetiology of RA subtypes.
RF- patients reported a longer delay from the onset of
symptoms until a diagnosis was made. This is another
novel finding for which we suggest three possible explana-
tions. First, RF- status is associated with milder forms of
RA and fewer clinical signs on presentation [83]. This
makes the subtype more difficult for clinicians to diagnose,
creating the diagnostic delay. Second, RF- patients score
higher on measures of neuroticism [59], which renders
them more sensitive to physical complaints and more
likely to seek medical treatment, even if clinical signs have
not yet fully developed. Third, RF- patients are more likely
to report somatization symptoms [26], knowledge of
which may bias the general practitioner to misdiagnose
the presentation as a somatization disorder.
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Limitations
Our study has three main limitations. First, while we used
a comprehensive, validated instrument to assess trait emo-
tional intelligence, we were unable to employ validated
instruments to assess depression or rheumatoid factor sta-
tus. For these two variables, we used a rapid method of
self-assessment by single question only. This was dictated
by the nature of our research, which was explorative/for-
mative, rather than definitive/summative. Second, while
the differences between RA versus controls reached strict
significance, those between RF+ and RF- subtypes lost
their significance after Bonferroni adjustment. Thus, our
findings should be considered as indicative and would
need to be replicated on larger samples with a full battery
of validated instruments. Third, our sample was not strati-
fied, but limited to members of patient societies. Further-
more, our response rate was only 25%, so the sample
might be weighted toward those who spend more time on
the internet, those who are more comfortable with submit-
ting data over the internet, or those who are particularly
interested in personality and emotionality. Future research
should make an effort to recruit from a broader base of
eligible patients.
Conclusions
While previous work may have suggested that RA patients
do not differ to healthy controls in their global trait EI
scores, this paper suggests that they do score differently
on eight specific trait EI personality facets. Each of these
may, in theory, leave them vulnerable to chronic stressors
and potential HPA axis dysregulation. While the exact
mechanisms are still unclear, emotion-related personality
traits appear to play a role as modulators or co-factors in
the complex cascade of events that trigger the pathogen-
esis of RA. Accordingly, future longitudinal studies investi-
gating the causes of RA would benefit from incorporating
trait EI personality factors alongside primary variables of
interest.
Our exploratory data suggest that RA patients may
divide into two subtypes. The majority group is RF+,
characterized by low depression, low emotional expres-
sion and a short wait time from onset until diagnosis.
The minority group is RF-, with high depression, high
emotional expression and a longer wait time from onset
until diagnosis. These findings are in keeping with the
perspective that RA is a highly heterogeneous disease.
The etiological mechanisms of RA may be better under-
stood if future studies explicitly make the assumption of
heterogeneity, and take a systems science approach to
study design in order to assess as many variables as possi-
ble and to include as many subjects as possible. This
would enable researchers to zoom in on the pathological
pathways behind ever-smaller subtypes, allowing us to ulti-
mately personalize the management and prevention of
each subtype accordingly. For subgroup analysis, research-
ers should assess gender, depression, rheumatoid factor,
delay time from onset until diagnosis and a variety of per-
sonality traits (emotional expression, psychoticism and
neuroticism may be particularly useful when studying RF+
and RF- subgroups). These variables could be studied
alongside physical variables, such as genes, measures of
stress sensitivity and reactivity (for example, HPA axis
response, skin conductance, EEG congruence or heart rate
variability), and cytokine profiles or cytokine responsivity
patterns, in order to develop a systematic and comprehen-
sive understanding of the role of stress in causing and per-
petuating RA.
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